What's Going On With Capricor Therapeutics Stock Friday?
Portfolio Pulse from Dylan Berman
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher after the company announced positive long-term benefits of deramiocel for treating Duchenne muscular dystrophy (DMD). The study showed improvements in cardiac and skeletal functions, based on the ongoing HOPE-2 open label extension study.
June 28, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics shares are up 4.39% following the announcement of positive long-term benefits of deramiocel for treating Duchenne muscular dystrophy. The study showed significant improvements in cardiac and skeletal functions.
The positive results from the deramiocel study are likely to boost investor confidence in Capricor Therapeutics, leading to a short-term increase in stock price. The improvements in cardiac and skeletal functions are significant for the treatment of DMD, a critical area of focus for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100